Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $64
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $69 to $64.
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $69 to $64.